Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY3323795
- Development stage
- Phase 1
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LY3323795 is a small molecule drug developed by Eli Lilly for the treatment of Alzheimer's disease. It acts as a selective inhibitor of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1), also known as beta-secretase 1. By inhibiting BACE1, LY3323795 is designed to prevent the formation and deposition of beta-amyloid (Aβ) plaques in the brain, which are considered an early and necessary event in the pathogenesis of Alzheimer's disease. The drug has undergone phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects.
- Other names
- LY-3323795LY3323795LY 3323795
02
Targets
BACE1 (Beta-site APP-cleaving enzyme 1)
Beyond the preview
Go deeper on LY3323795.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY3323795.